✦ LIBER ✦

The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri)

✍ Scribed by Lenworth N Johnson; Gregory B Krohel; Richard W Madsen; Glenville A March Jr

Book ID: 117328903
Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 199 KB
Volume: 105
Category: Article
ISSN: 0161-6420
DOI: 10.1016/s0161-6420(98)91234-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Profiles of Obesity, Weight Gain, and Qu

Profiles of Obesity, Weight Gain, and Quality of Life in Idiopathic Intracranial Hypertension (Pseudotumor Cerebri)

✍ Anthony B. Daniels; Grant T. Liu; Nicholas J. Volpe; Steven L. Galetta; Mark L. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 699 KB

Clinical review: the surgical treatment

Clinical review: the surgical treatment of idiopathic pseudotumour cerebri (idiopathic intracranial hypertension)

✍ PW Brazis 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 115 KB

The Use of Acetazolamide in Idiopathic I

The Use of Acetazolamide in Idiopathic Intracranial Hypertension During Pregnancy

✍ Andrew G. Lee; Misha Pless; Julie Falardeau; Tammy Capozzoli; Michael Wall; Rand 📂 Article 📅 2005 🏛 Elsevier Science 🌐 English ⚖ 147 KB

Recurrence of idiopathic intracranial hy

Recurrence of idiopathic intracranial hypertension after weight loss: the carrot craver

✍ Sean P Donahue 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 155 KB

50 Years Ago in The Journal of Pediatric

50 Years Ago in The Journal of Pediatrics: Pseudotumor cerebri: Benign intracranial hypertension

✍ Paul Graham Fisher 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 53 KB

High pseudotumor cerebri incidence in tr

High pseudotumor cerebri incidence in tretinoin and arsenic treated acute promyelocytic leukemia and the role of topiramate after acetazolamide failure

✍ Smith, Morgan B.; Griffiths, Elizabeth A.; Thompson, James E.; Wang, Eunice S.; 📂 Article 📅 2014 🏛 Elsevier 🌐 English ⚖ 231 KB

Dual differentiation therapy with arsenic trioxide and tretinoin (all-__trans__-retinoic acid; ATRA) for the management of low and intermediate risk acute promyelocytic leukemia has recently been recommended by the National Comprehensive Cancer Network. Some less common toxicities of the combination